公开(公告)号：US20140235559A1

公开(公告)日：2014-08-21

申请号：US14004746

申请日：2011-06-15

申请人： Sung-Wuk Kim ,  Sung-Soo Jun ,  Chang-Hee Min ,  Ja-Seong Koo ,  Jin-Wook Kim ,  Yong-Eun Kim ,  Sang-Ouk Sun

发明人： Sung-Wuk Kim ,  Sung-Soo Jun ,  Chang-Hee Min ,  Ja-Seong Koo ,  Jin-Wook Kim ,  Yong-Eun Kim ,  Sang-Ouk Sun

IPC分类号： A61K31/7004 ,  A61K9/48 ,  A61K9/28 ,  A61K31/155 ,  A61K31/506

CPC分类号： A61K31/7004 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/155 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

摘要翻译： 公开了包含苯乙双胍或其药学上可接受的盐和2-脱氧-D-葡萄糖作为活性成分的抗癌药物组合物。 与各成分相比，这些成分彼此协同作用，因此对癌细胞的生长具有更强的抑制活性。 此外，协同抗癌活性允许以较低的量使用单独的药物，这导致副作用的发生减少。 此外，成分的时间延迟释放或给药降低了血液乳酸水平，以显着减轻乳酸性酸中毒的不利影响，并发挥高抗癌作用。 特别地，药物组合物可以配制成对治疗有效的剂型，增加受试者的药物依从性。